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Abstract
Background: T cells exhibit heterogeneous functional states in the tumor microenvironment. Immune checkpoint
inhibitors (ICIs) can reinvigorate only the stem cell-like progenitor exhausted T cells, which suggests that inhibiting
the exhaustion progress will improve the efficacy of immunotherapy. Thus, regulatory factors promoting T cell
exhaustion could serve as potential targets for delaying the process and improving ICI efficacy.
Methods: We analyzed the single-cell transcriptome data derived from human melanoma and non-small cell lung
cancer (NSCLC) samples and classified the tumor-infiltrating (TI) CD8+ T cell population based on PDCD1 (PD-1)
levels, i.e., PDCD1-high and PDCD1-low cells. Additionally, we identified differentially expressed genes as candidate
factors regulating intra-tumoral T cell exhaustion. The co-expression of candidate genes with immune checkpoint
(IC) molecules in the TI CD8+ T cells was confirmed by single-cell trajectory and flow cytometry analyses. The loss-
of-function effect of the candidate regulator was examined by a cell-based knockdown assay. The clinical effect of
the candidate regulator was evaluated based on the overall survival and anti-PD-1 responses.
Results: We retrieved many known factors for regulating T cell exhaustion among the differentially expressed
genes between PDCD1-high and PDCD1-low subsets of the TI CD8+ T cells in human melanoma and NSCLC. TOX
was the only transcription factor (TF) predicted in both tumor types. TOX levels tend to increase as CD8+ T cells
become more exhausted. Flow cytometry analysis revealed a correlation between TOX expression and severity of
intra-tumoral T cell exhaustion. TOX knockdown in the human TI CD8+ T cells resulted in downregulation of PD-1,
TIM-3, TIGIT, and CTLA-4, which suggests that TOX promotes intra-tumoral T cell exhaustion by upregulating IC
proteins in cancer. Finally, the TOX level in the TI T cells was found to be highly predictive of overall survival and
anti-PD-1 efficacy in melanoma and NSCLC.
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Conclusions: We predicted the regulatory factors involved in T cell exhaustion using single-cell transcriptome
profiles of human TI lymphocytes. TOX promoted intra-tumoral CD8+ T cell exhaustion via upregulation of IC
molecules. This suggested that TOX inhibition can potentially impede T cell exhaustion and improve ICI efficacy.
Additionally, TOX expression in the TI T cells can be used for patient stratification during anti-tumor treatments,
including anti-PD-1 immunotherapy.
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Background
T cell dysfunction has been reported to be a hallmark of
cancers [1]. However, the molecular mechanisms under-
lying tumor-infiltrating (TI) CD8+ T cell exhaustion, es-
pecially the alterations in the transcriptional regulatory
networks in cancer, are not completely understood. T
cell exhaustion develops progressively during chronic
antigen stimulation, which results in a heterogeneous
population of exhausted T cells [2]. Recent studies have
revealed that the progenitor exhausted and terminally
exhausted CD8+ T cells, which are the subsets of
exhausted T cells, exhibit differential intrinsic effector
functions and reinvigoration potential via programmed
cell death 1 (PD-1) inhibition (reviewed in [2]). The pro-
genitor exhausted and terminally exhausted TI CD8+ T
cell subsets exhibiting distinct epigenetic and transcrip-
tional characteristics have been detected in the tumor
microenvironment [3, 4].
TCF7 (also known as TCF1) is reported to be an es-
sential transcription factor (TF) in the progenitor
exhausted CD8+ T cells, which exhibit a stem cell-like
phenotype [2]. However, a master regulator that induces
the differentiation of progenitor exhausted CD8+ T cells
into terminally exhausted CD8+ T cells has not been
identified. PD-1 expression is closely correlated with the
severity of T cell exhaustion. Thus, several studies have
attempted to identify a master regulator that triggers
CD8+ T cell exhaustion by focusing on PD-1 expression
and the associated regulatory factors. Various regulators,
such as eomesodermin (EOMES) and SMAD4, have been
reported to be characteristically expressed in the termin-
ally exhausted CD8+ T cells [2, 5]. However, the role of
these regulators in the direct regulation of the exhaustion
program remains unclear. A detailed understanding of the
mechanisms underlying the establishment and mainten-
ance of terminally exhausted CD8+ T cells will aid in the
development of novel therapeutic strategies for cancer.
In this study, we demonstrate a strategy for predicting
the genes involved in cellular differentiation based on
single-cell transcriptome data analysis. This analysis was
used to identify the TFs that promote CD8+ T cell ex-
haustion in tumors. The single-cell transcriptome data
of human melanoma and non-small cell lung cancer
(NSCLC) samples were analyzed to systematically pre-
dict the regulatory factors involved in T cell exhaustion.
This analysis identified that several genes such as thymo-
cyte selection-associated high mobility group box gene
(TOX) and immune checkpoint (IC) genes can regulate
T cell exhaustion. The analysis of expression dynamics
along the pseudo-temporally ordered CD8+ T cells from
human tumors revealed that the expression of TOX in-
creases with the exhaustion of CD8+ T cells. Addition-
ally, TOX positively regulated the expression of PD-1,
TIM-3, TIGIT, and CTLA-4 in the human TI CD8+ T
cells. This suggested that TOX is a key TF that promotes
T cell exhaustion by inducing IC molecules in human
cancers. Finally, the expression levels of TOX in the TI
T cells could predict the overall survival and response to
anti-PD-1 therapy in human melanoma and NSCLC.
These results suggest that TOX levels can be used for
patient stratification during anti-cancer treatment, in-
cluding immunotherapy, and that TOX can be targeted
in the background of immune checkpoint inhibitor (ICI)
therapy.
Methods
Preprocessing of single-cell transcriptome data and
differential expression analysis
We analyzed the single-cell transcriptome data of tumor
samples derived from 17 patients with melanoma
(GSE72056) [6] and 14 patients with NSCLC
(GSE99254) [7]. The transcriptome data were generated
by full-length single-cell RNA sequencing (scRNA-seq)
in a single batch. Expression level (E) based on the read
count data from melanoma samples were normalized as
Ei,j = log2(TPM/10 + 1) (for the ith gene of the jth cell).
Cells with fewer than 1700 detected genes (defined by at
least 1 mapped read) or exhibiting an average house-
keeping expression level (as defined above) of less than 3
were excluded. The read count data from NSCLC sam-
ples were normalized by scran [8] method and centered
by patient. Low-quality cells were filtered out if the
number of expressed genes was smaller than [(median of
all cells) − 3 × (median absolute deviation)] or if the
mitochondrial gene count proportion of a cell was larger
than 10%. Cells were also discarded if the TPM value of
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CD3D was < 3, TPM of CD8A < 3, or CD4 > 30 for
fluorescence-activated cell sorting (FACS)-sorted CD8+
T cells and if the TPM of CD4 < 3 or CD8A > 30 for
FACS-sorted CD4+ T cells. The preprocessing resulted
in 4645 cells from melanoma samples and 11,769 cells
from NSCLC samples. We used the normalized expres-
sion data as provided by the original studies for both
scRNA-seq datasets. To investigate the transition of
transcriptional states of CD8+ T cells in the tumor
microenvironment, we used the single-cell transcriptome
profiles for CD8+ T cell subset of the datasets. For the
human melanoma dataset, we first isolated the cells an-
notated as “T cell” and performed clustering analysis
using the Seurat v3 R package. We annotated each clus-
ter based on the marker gene expression for major cell
types, and isolated 1072 cells from the cluster annotated
as CD8+ T cells based on the expression of CD8, but not
of CD4 (CD4−CD8+). For the human NSCLC dataset, we
used only 2123 cells annotated as “TTC cell” (tumor
cytotoxic T cell) for CD8+ T cells. We divided the CD8+
T cells into 2 subsets based on the expression level of
PDCD1 (also known as PD-1) into PDCD1-low (cells
with below median EPDCD1) and PDCD1-high (cells with
above median EPDCD1). Next, we analyzed the differential
expression of each gene between PDCD1-low and
PDCD1-high subsets using the Wilcoxon rank-sum test.
The difference was considered statistically significant
when the P value was less than 0.05 (*), 0.01 (**), 0.001
(***), and 0.0001 (****). For both tumor scRNA-seq
datasets, we selected the differentially expressed genes
(DEGs) with P < 0.001. We further filtered out candi-
date genes with the mean of normalized expression
value lower than a threshold (1 for melanoma and 2
for NSCLC) in both subsets. This filtration process
resulted in 175 and 92 DEGs for melanoma and
NSCLC datasets, respectively (Additional file 1: Table
S1).
Dimension reduction and visualization of single-cell
transcriptome data
To visualize the relationship among individual cells
based on high-dimensional gene expression data, we
used t-stochastic neighbor embedding (tSNE) [9], which
is one of the most popular methods for dimension re-
duction. We conducted the tSNE analysis using the Seu-
rat v3 R package with the following parameters:
perplexity, 30; number of iterations, 1000. To find the
optimal number of PCA dimension, we ran “JackStraw”
function of Seurat v3 and chose the largest dimension
with P < 0.05. We projected the individual cells on the
first two tSNE dimensions. Additionally, we used the
violin plots to present the density distribution of cells
with specific gene expression levels in the PDCD1-low
and PDCD1-high subsets.
Single-cell trajectory analysis
To investigate the kinetics of gene expression during
CD8+ T cell differentiation in the tumor microenviron-
ment, we performed single-cell trajectory analysis using
the Monocle 2 software [10]. The scRNA-seq profiles of
CD8+ T cells derived from human melanoma
(GSE72056) [6] were used to reconstruct the single-cell
trajectories for the effector, memory, and exhausted
states. We defined the three T cell states of stable end-
point based on the expression of three marker genes
[11–13]. The “classifyCells” function and marker expres-
sion data were used to classify the T cells into three cel-
lular states: effector state (CD62L−, CD127−, and
PDCD1−), exhausted state (PDCD1+), and memory state
(CD62L+ or CD127+). The cells belonging to multiple
states and those belonging to none of the three states
were assigned as “ambiguous” and “unknown” states, re-
spectively. The group-specific marker genes were se-
lected using the “markerDiffTable” function. Next, we
pseudo-temporally ordered the cells using the “reduce-
Dimension” and “orderCells” functions. The expression
dynamics along the trajectories were visualized using the
BEAM analysis tools in the Monocle 2 software. The sig-
nificance of upregulated expression in the exhausted T
cells (or memory T cells) relative to the effector T cells
was tested by one-tailed Mann-Whitney U test.
Clinical sample collection
For the flow cytometric analysis of immune cells, fresh
tumor specimens were provided by the Department of
Internal Medicine at the Severance Hospital, along with
permission to conduct the following study. We enrolled
35 patients with NSCLC and 15 patients with head and
neck squamous cell carcinoma (HNSCC) who were
treated between 2017 and 2019 in Korea. Detailed infor-
mation on human subjects has been listed in Add-
itional file 2: Table S2.
An internal cohort of patients with cancer undergoing
anti-PD-1 treatment
To study the correlation between TOX expression level
in the TI T cells and response to anti-PD-1 therapy, we
recruited 16 patients with NSCLC from Yonsei Cancer
Center, Seoul, Korea. The patients were administered
nivolumab or pembrolizumab. Patients exhibiting partial
response (PR) or stable disease (SD) for > 6 months were
classified as responders, while the patients exhibiting
progressive disease (PD) or SD for ≤ 6 months were clas-
sified as non-responders based on the Response Evalu-
ation Criteria in Solid Tumors (RECIST) ver. 1.1 [14].
The tumor samples were obtained from patients before
immunotherapy. Patient information is shown in
Additional file 2: Table S3-4.
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Bulk RNA sequencing data analysis of tumor samples
Bulk RNA sequencing was performed for 16 samples
from patients treated with the PD-1 inhibitor. Of the 16
tumor samples, 11 were fresh samples and 5 were
formalin-fixed paraffin-embedded (FFPE) samples. The
library was prepared from the samples using the TruSeq
RNA Access Library Prep Guide Part # 15049525 Rev. B
with the TruSeq RNA Access Library Prep Kit (Illu-
mina). RNA sequencing was performed in HiSeq 2500
(Illumina). The obtained sequencing data were processed
as per the manufacturer’s instructions. The read data
were aligned with the reference genome (GENCODE,
h19 (GRCh37.p13, release 19)) [15] using STAR-2.5.2a
[16]. The transcripts were quantified using feature-
Counts [17]. The correlation between the read count
values of genes between fresh and FFPE samples was
evaluated using Pearson’s correlation coefficient. The
correlations between intra-fresh sample, intra-FFPE sam-
ple, and fresh-FFPE samples as evaluated by Wilcoxon’s
rank-sum test were found to be significant.
Isolation of TI lymphocytes from the primary tumor
Primary tumor tissues were obtained by surgical resec-
tion of patient tumors and from tumors developed in
mice. The tissues were minced into 1 mm3 pieces and
digested with a solution containing 1 mg/mL collagenase
type IV (Worthington Biochemical Corp.) and 0.01 mg/
mL DNase I (Millipore Sigma Corp.) at 37 °C for 20 min.
The dissociated tissues were filtered using a 40-μm cell
strainer (Falcon, Corning) into the Roswell Park Memor-
ial Institute (RPMI)-1640 medium (Corning Inc., Corn-
ing). Tumor-infiltrating lymphocytes (TILs) were
separated using a Percoll gradient (Millipore Sigma
Corp.) and suspended in phosphate-buffered saline
(PBS) supplemented with 2% fetal bovine serum (FBS;
Biowest). The single-cell suspensions were stained with
the indicated fluorescent dye-conjugated antibodies.
Flow cytometric analysis
Single-cell suspensions were analyzed using the Cyto-
FLEX or CytoFLEX LX flow cytometers (Beckman
Coulter) after staining with the following antibodies for
murine tissues: CD4-BV785 (RM4-5), CD4-BV510
(RM4-5), CD8-Alexa Fluor 700 (53-6.7), CD8-PerCP-
Cy5.5 (53-6.7), PD-1-BV605 (29F.1A12), PD-1-BV421
(29F.1A12), TIM-3-BV605 (RMT3-23), TIM-3-PerCP-
Cy5.5 (B8.2C12), LAG-3-BV650 (C9B7W), and T-BET-
BV421 (4B10) antibodies (all from BioLegend); TIGIT-
BV785 (1G9) antibody (BD Bioscience); 2B4-FITC
(eBio244F4) and EOMES-APC (Dan11mag) antibodies
(all from Invitrogen); CTLA-4-Alexa Fluor 700 (63828)
antibody (R&D Systems); TCF1-Alexa Fluor 488
(C63D9) antibody (Cell Signaling); and TOX-PE
(REA473), REA Control (I)-PE (REA293), NR4A1(NUR77)-
APC (REA704), and REA Control-APC (REA293) anti-
bodies (all from Miltenyi Biotec). Dead cells were stained
using the Live/Dead Fixable Near-IR Dead Cell Stain Kit
(Invitrogen). For TF staining, the TI lymphocytes were fixed
and permeabilized using the FOXP3 fixation/
permeabilization solution (eBioscience). T-BET, EOMES,
TCF1, NR4A1, and TOX antibodies or their isotype control
antibodies were used for staining after permeabilization.
The following antibodies were used for human sample
staining: CD3-BV785 (OKT3), CD8-BV605 (RPA-T8),
CD8-BV510 (RPA-T8), CD8-BV650 (RPA-T8), and PD-
1-BV421 (EH12.2H7) antibodies (all from BioLegend);
TIM-3-BV605 (F38-2E2), LAG-3-FITC (11C3C65),
CTLA-4-PE-Cy7 (BNI3), 2B4-Alexa Flour 700 (C1.7),
IFN-γ-APC (4S.B3), and TNF-α-PE-Cy7 (MAb11) anti-
bodies; TIM-3-Alexa Fluor 488 (344823) and TIGIT-
APC (741182) antibodies (all from R&D Systems); CD4-
APC-H7 (L200), TIGIT-BV510 (741182), and T-BET-
BV650 (O4-46) antibodies (all from BD Biosciences);
TOX-PE (REA473), REA Control (I)-PE (REA293),
NR4A1-APC (REA704), and REA Control-APC (REA293)
antibodies (all from Miltenyi Biotec); TCF1-Alexa Fluor
488 (C63D9) antibodies (Cell Signaling); and EOMES-
APC (WD1928), TOX-PE (TXRX10), and Rat IgG2a
kappa isotype control-PE (eBR2a) antibodies (Invitrogen).
Dead cells were excluded by staining with the Live/Dead™
Fixable Red Dead Cell Stain Kit (Invitrogen). For
staining the intra-cellular cytokines and TFs, the cells
were fixed and permeabilized with the Foxp3 fixation/
permeabilization solution (eBioscience), followed by
staining with antibodies against IFN-γ, TNF-α, T-
BET, EOMES, TCF1, NR4A1, and TOX, or their iso-
type controls. Cells were analyzed using the FlowJo
software (Tree Star Inc.). The gating strategy used to
identify the human TI CD8+ T cells is shown in
Additional file 2: Figure S1A.
In vivo tumor models
Five to 6-week-old female C57BL/6 mice and Balb/c
mice were purchased from Charles River Laboratories
and The Jackson Laboratory, respectively. MC38 colon
cancer cells, TC-1 lung cancer cells, or LLC1 lung can-
cer cells were injected subcutaneously (106 cells) into
the C57BL/6 mice. The CT26 colon cancer cells were
injected subcutaneously (106 cells) into the Balb/c mice.
The mice were euthanized at day 21 post-tumor cell
injection.
TOX knockdown in human TI CD8+ T cells
The primary lung cancer specimens were dissociated
using gentle MACS Dissociator (Miltenyi Biotec) and
Human Tumor Dissociation Kit (Miltenyi Biotec), fol-
lowing the manufacturer’s instructions. The TILs were
transfected with TOX siRNA—that suppresses TOX
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expression—or with control siRNA (Thermo Fisher Sci-
entific) using the Neon transfection system (Invitrogen).
The transfected TI lymphocytes were stimulated with
the anti-CD3 antibody (1 μg/mL, OKT3, Miltenyi Biotec)
coated on the plate for 84 h. For the functional analysis,
the cells were re-stimulated for another 6 h with the
anti-CD3 antibody in the presence of both GolgiStop
and GolgiPlug (BD Biosciences) and stained with anti-
bodies against IFN-γ and TNF-α. Gene knockdown was
confirmed by flow cytometry.
Statistical test for experimental data
The statistical significance was analyzed using two-tailed
unpaired and paired Student’s t tests in the Prism 5.02
software (GraphPad). The data are expressed as mean ±
standard error of mean (SEM). The difference was con-
sidered statistically significant when the P value was less
than 0.05 (*), 0.01 (**), 0.001 (***), and 0.0001 (****).
Survival analysis and anti-PD-1 response analysis
We evaluated the T cell-specific TOX gene expression
and demonstrated the correlation between TOX expres-
sion level in T cells and that in the CD8+ T cells using
single-cell transcriptome data obtained from human
melanoma samples [6]. To evaluate the clinical effect of
TOX expression in only TI T cells, we normalized TOX
expression to the expression level in the TI T cells using
the geometric mean of the expression levels of CD3D,
CD3E, and CD3G.
Survival analysis based on the transcriptome and clin-
ical data compiled from The Cancer Genome Atlas
(TCGA) for melanoma (SKCM, skin cutaneous melan-
oma) and NSCLC (LUAD, lung adenocarcinoma, and
LUSC, lung squamous cell carcinoma) was performed.
The bulk RNA-seq data for tumor samples were down-
loaded from the Xena database (https://xena.ucsc.edu/),
while the clinical data were downloaded from TCGA-
CDR [18]. For the survival analysis of patients with
NSCLC, we used that data of patients exhibiting top
25% tumor mutation burden. Next, we compared the
overall survival rates of patients exhibiting top 30% TOX
level (TOX-high) with those of all other patients (TOX-
low). The significance of difference between survival
times among groups was examined using the log-rank
test.
For analyzing the correlation between anti-PD-1 re-
sponse and TOX expression levels in the TI T cells, we
analyzed the bulk RNA-seq data along with clinical in-
formation for four independent cohorts of patients who
underwent anti-PD-1 immunotherapy, including three
published reports [19–21]. Similar to that in the survival
analysis, we normalized the TOX expression and gener-
ated waterfall plots after segregating the patients based
on the mean TOX expression values. For the Hugo et al.
[19] dataset, we classified patients annotated as “Partial
Response” and “Complete Response” into the responder
group, and those annotated as “Progressive Disease” into
the non-responder group. For the Jung et al. [21] data-
set, we classified the patients annotated as DCB (Durable
Clinical Benefit) into the responder group and those an-
notated as NDB (Non-Durable Benefit) into the non-
responder group. For the Riaz et al. [20] dataset, we ex-
cluded patients annotated as “Stable Disease” and classi-
fied the rest of the patients into two groups in a manner
similar to that used for generating the Hugo et al. data-
set. To evaluate the predictive power of TOX expression
in the TI T cells for governing the responses to anti-PD-
1 therapy, we prioritized the patients by sorting the pa-
tients exhibiting the lowest TOX level in the TI T cells
and performed receiver operating characteristic (ROC)
analysis.
Results
Subset analysis of single-cell transcriptome profiles of
CD8+ T cells for identifying regulators involved in T cell
exhaustion
The distinct cellular states can be often depicted using
the expression of single marker genes. Thus, we can
identify key genes involved in the progression of T cell
exhaustion by analyzing the DEGs between the progeni-
tor exhausted T cells and terminally exhausted T cells.
However, the exhausted CD8+ T cells in the tumor
microenvironment exhibit a continuous spectrum of
transcriptional states depending on the exhaustion sever-
ity levels [22]. Therefore, we developed a strategy for
identifying the genes involved in T cell exhaustion using
single-cell transcriptome data (Fig. 1a). The exhausted
CD8+ T cells exhibiting intermediate PD-1 expression
can be reinvigorated by PD-1 inhibition, whereas those
exhibiting high PD-1 expression are refractory to this ef-
fect [23]. Therefore, we segregated the TI CD8+ T cells
into two subsets based on the median expression value
of PDCD1, i.e., PDCD1-high and PDCD1-low subsets.
The localized distribution of PDCD1-high cells in the
two-dimensional latent space of the tSNE plot indicated
that the PDCD1 marker can aid in distinguishing be-
tween the terminally exhausted and progenitor
exhausted cells. The DEGs between the two subsets
might be the potential factors associated with T cell ex-
haustion, which can also be confirmed from the similar
distribution of DEG-high cells in the same two-
dimensional latent space.
This strategy was applied to analyze the single-cell
transcriptome profiles of CD8+ T cells derived from mel-
anoma [6] (Fig. 1b), which revealed the localized distri-
bution of PDCD1-high cells in the tSNE plot. We
identified 175 DEGs between the PDCD1-high and
PDCD1-low subsets using the Wilcoxon test (P < 0.001)
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Fig. 1 (See legend on next page.)
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(Additional file 1: Table S1A). Notably, the expression
levels of IC genes, such as HAVCR2 (also known as
TIM-3), CTLA4, and TIGIT in the PDCD1-high subset
were higher than those in the PDCD1-low subset. Add-
itionally, the distribution patterns of the IC genes in the
DEG-high cells and those in the PDCD1-high cells were
similar in the tSNE plot. A subset analysis of single-cell
transcriptome profiles of CD8+ T cells derived from
NSCLC [7] (Fig. 1c) revealed 92 DEGs (Additional file 1:
Table S1B). The single-cell transcriptome profile analysis
of NSCLC samples revealed that the IC genes in the
PDCD1-high subset were upregulated. The correlation
between PDCD1 expression and other IC genes validated
the effectiveness of subset analysis of single-cell tran-
scriptome data for identifying the genes involved in T
cell exhaustion. We found that neither PDCD1-high nor
PDCD1-low subset were severely biased in distribution
of cells from each patient in both single-cell transcrip-
tome datasets reanalyzed, indicating that the observed
differential expression is not based on patient-specific ef-
fect (Additional file 2: Figure S2).
To identify the key trans-acting regulators involved in
the regulation of intra-tumoral T cell exhaustion, we fo-
cused on 13 and 5 TFs (annotated by Ravasi et al. [24])
among the DEGs identified from melanoma and NSCLC
samples, respectively. We successfully retrieved several
TFs previously reported to be involved in T cell exhaus-
tion, such as BATF [25], NFATC1 [25], and PRDM1
[26]. This further highlighted the effectiveness of pre-
dicting regulatory factors using single-cell transcriptome
data. We observed that the TFs are differentially
expressed in the PDCD1-high and PDCD1-low subsets
among the melanoma or NSCLC samples (Fig. 1d).
Some regulators may be specifically involved in particu-
lar cancer types. The tumor specificity identified based
on the statistical analysis must be evaluated by follow-up
functional analysis. Notably, TOX was the only candi-
date TF identified in both melanoma and NSCLC sam-
ples. The distribution patterns of TOX-high cells and
PDCD1-high cells were similar in the latent space of the
tSNE plot for both melanoma and NSCLC, which were
similar to the distribution patterns of IC genes (see
Fig. 1b, c).
TOX and IC genes exhibited similar expression dynamics
along the single-cell trajectories for TI CD8+ T cells
TI T cells that are initially in the effector state (Teff)
soon start becoming dysfunctional and get converted
into exhausted T cells (Texh) as a result of the highly im-
munosuppressive tumor microenvironment. A subset of
persisting Teff cells differentiates into long-lived and self-
renewable memory T cells (Tmem). We hypothesized that
if TOX promotes T cell exhaustion, the expression dy-
namics of TOX during the transition from Teff to Texh
should differ from that during the transition from Teff to
Tmem. To test this hypothesis, we reconstructed the
single-cell trajectories composed of pseudo-temporally
ordered CD8+ T cells across the three distinct T cell
states using the Monocle 2 software [10]. All three
single-cell trajectories were significantly enriched for the
corresponding cell type assigned based on marker ex-
pression (P < 2.2e−16 for exhausted state and memory
state, P = 7.07e−07 for effector state by binomial test)
(Fig. 2a), which validates the established trajectories of T
cell differentiation in tumor. We found that none of the
three branches was severely biased in distribution of
cells from each patient, indicating that the observed dif-
ferential enrichment of three distinct T cell states among
trajectories is not based on patient-specific effect
(Fig. 2b).
The expression of IC genes, such as CTLA4, HAVCR2,
LAG3, PDCD1, and TIGIT, was upregulated along the
pseudotime of CD8+ T cell exhaustion (Fig. 2c, d). Com-
pared to the effector state, the exhaustion state (but not
the memory state) was associated with significantly en-
hanced expression of IC genes (P values are by one-
tailed Mann-Whitney U test) (Fig. 2d). Notably, the
changes in the expression of TOX followed an identical
trend along the pseudotime trajectories (Fig. 2c, d). As
the expression level of IC molecules is correlated with
the severity of CD8+ T cell exhaustion, these results in-
dicate that TOX expression is correlated with the sever-
ity of CD8+ T cell exhaustion in tumors.
Further, we examined the expression dynamics of
other TFs reported to be involved in T cell exhaustion.
The expression of NR4A1, a TF that induces T cell ex-
haustion [27, 28], was upregulated at later stages of the
exhaustion state. However, the upregulated expression
(See figure on previous page.)
Fig. 1 Prediction of regulatory factors involved in mediating intra-tumoral T cell exhaustion by single-cell transcriptome analysis. a Overview of
the strategy used for identifying the candidate genes associated with T cell exhaustion using single-cell transcriptome profiles of TI CD8+ T cells.
b, c Correlation between the expression levels of immune checkpoint (IC) genes and TOX with those of PDCD1, which is a marker of the
exhaustion state in b melanoma (derived from GSE72056) and c non-small cell lung cancer (NSCLC) (derived from GSE99254). Individual cells that
express a gene of interest at values higher than the threshold value are indicated in red in the t-stochastic neighbor embedding (tSNE) plots. d
Examples of differentially expressed transcription factors (TFs) between the PDCD1-high and PDCD1-low cells in melanoma or NSCLC. The
distribution patterns of gene expression in the single-cell for PDCD1-low subset and PDCD1-high subset are summarized as violin plots. The
difference was tested using the Wilcoxon rank-sum test (**** P < 0.0001)
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Fig. 2 (See legend on next page.)
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during the entire exhaustion state was not significant
(P = 0.1209). Recently, NFAT1 (also known as NFATC2)
and NFAT2 (also known as NFATC1) were reported to
be the TFs that promote T cell exhaustion [29–31]. The
expression of NFATC1 (P = 7.637e−05), but not that of
NFATC2 (P = 0.8299), in the exhausted state was signifi-
cantly higher than that in the effector state, which was
in agreement with the results of a previous study [31].
Interestingly, the same study also demonstrated that
TOX expression is induced by NFAT2 (NFATC1).
TOX2 was also reported to be involved in CD8+ T cell
exhaustion [28, 30, 32]. We could not detect the upregu-
lated expression of TOX2 in the TI T cells as the expres-
sion was low. However, the expression level of TOX2 in
the exhausted state was significantly higher than that in
the effector state (P = 1.915e−05). TCF7 (also known as
TCF1) is a key regulator of progenitor exhausted T cells
[33–37]. The expression of TCF7 in the memory state
was significantly higher than that in the effector state
(P = 7.01e−08). This result is consistent with that of a
previous study that reported the essential roles of Tcf-1
in establishing the CD8+ T cell memory [38] and the
memory-like cell functions of Tcf-1+CD8+ T cell in
chronic infections [36] in the mouse model. Conse-
quently, the overall consistency of the observed expres-
sion dynamics of known TFs for T cell exhaustion in
single-cell trajectories in conjunction with the previous
studies validates our reconstructed single-cell trajectories
of T cell differentiation in tumors.
TOX protein level correlated with the severity of intra-
tumoral CD8+ T cell exhaustion in human cancers
The correlation between TOX protein expression and se-
verity of intra-tumoral T cell exhaustion was evaluated by
flow cytometric analysis of TI lymphocytes isolated from
human primary tumor specimens from patients with
NSCLC or HNSCC who underwent surgical resection at
the Severance Hospital (Additional file 2: Table S2). TOX
expression was positively correlated with the expression of
various IC molecules, such as PD-1, TIM-3, and TIGIT—
at protein level—in the TI CD8+ T cells isolated from both
NSCLC and HNSCC tumor tissues (Fig. 3a). Additionally,
the proportion of TOX+ TI CD8+ T cells was significantly
associated with the expression of IC molecules (Fig. 3b).
The TOX+ TI CD8+ T cells were significantly enriched in
the population expressing other IC molecules, such as
CTLA-4, LAG-3, and 2B4 (Additional file 2: Figure S1B).
The PD-1+TIM-3+ CD8+ T cells exhibit the terminally
exhausted phenotype, while the PD-1+TIM-3− CD8+ T
cells exhibit the progenitor exhausted phenotype in
chronic viral infection as well as tumors [39, 40]. Thus, we
sub-gated the population into PD-1−TIM-3−, PD-1+TIM-
3−, and PD-1+TIM-3+ cells and compared the TOX levels
in these three subsets. Among the subsets, the terminally
exhausted TI CD8+ T cells exhibited significantly high
TOX level. Each population can be arranged in the follow-
ing order of decreasing TOX expression: PD-1+TIM-3+ >
PD-1+TIM-3− > PD-1−TIM-3− (Fig. 3c). Flow cytometric
analysis of mouse TI CD8+ cells isolated from various can-
cer models, including MC38 colon cancer, CT26 colon
cancer, TC-1 lung cancer, and LLC1 lung cancer, revealed
a similar correlation between TOX expression and TI
CD8+ T cell exhaustion severity (Additional file 2:
Figure S3 and S4A). These results strongly suggest
that TOX expression is closely associated with the se-
verity of TI CD8+ T cell exhaustion.
We also investigated the correlation between other TFs
and TI CD8+ T cell exhaustion severity. The expression
patterns of NR4A1, T-BET, EOMES, and TCF1—which
are reported to regulate T cell exhaustion—were exam-
ined in the human NSCLC and mouse tumors, including
MC38, CT26, TC-1, and LLC1. The expression levels of
other TFs did not correlate with PD-1 expression in the
TI CD8+ T cells from human NSCLC tumors
(Additional file 2: Figure S1C). Similarly, the expression
levels of TFs, such as NR4A1 and T-BET, were not
correlated with PD-1 expression in the TI CD8+ T cells
from various mouse tumors (Additional file 2: Figure
S4B). The results of the flow cytometric analysis agreed
with those of the single-cell trajectory analysis. The ana-
lysis revealed that the expression of NR4A1 and TCF7 in
the exhausted T cells was not significantly upregulated
(See figure on previous page.)
Fig. 2 Gene expression dynamics along the pseudotime of T cell exhaustion. a Single-cell trajectories across three distinct states of CD8+ T cells
derived from human melanoma (GSE72056). The cells were classified into different T cell types using Monocle 2 based on the following criteria:
effector (CD62L−, CD127−, PDCD1−), exhausted (PDCD1+), memory (either CD62L+ or CD127+), ambiguous (classified into multiple cell types), and
unknown (classified into none of the cell types). The ambiguous cells and unknown cells were not visualized in the t-stochastic neighbor
embedding (tSNE) plot. Based on the enriched cell type, the cells were classified into three states (of CD8+ T cell): effector, exhausted, and
memory states (P < 2.2e−16 for exhausted state and memory state, P = 7.07e−07 for effector state by the binomial test). b Distribution of CD8+ T
cells from each patient of the dataset across three branches of single-cell trajectories. c, d The expression dynamics of immune checkpoint (IC)
genes and TOX along the pseudotime of CD8+ T cells in two alternative trajectories from the effector state to the memory state or to the
exhausted state were summarized using BEAM analysis (c) and scatter plots with regression curves (right column for the trajectory toward
exhausted state and left column for the trajectory toward memory state) (d). The significance of upregulated expression in the exhausted T cells
(or memory T cells) relative to the effector T cells was tested by one-tailed Mann-Whitney U test
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when compared to that in the effector T cells (see Fig. 2d).
Notably, in some mouse tumors, the expression levels of
EOMES and TCF1 were negatively and positively corre-
lated with PD-1 expression, respectively. These results in-
dicate that among the TFs reported to be involved in
CD8+ T cell exhaustion, only the expression level of TOX
was positively correlated with PD-1 expression.
TOX knockdown disrupts expression of checkpoint
molecules in human TI CD8+ T cells and restores their
anti-tumor function
As TOX expression was positively correlated with the
severity of CD8+ T cell exhaustion, we hypothesized that
TOX is a positive regulator of the exhaustion process in
human cancers. Therefore, we evaluated the effect of
TOX loss of function on IC molecules in the human TI
Fig. 3 Correlation of TOX expression with the severity of CD8+ T cell exhaustion in human tumors. a–c Flow cytometric analysis of the tumor-
infiltrating (TI) CD8+ T cells isolated from human non-small cell lung cancer (NSCLC) (n = 20) and head and neck squamous cell carcinoma (HNSC
C) (n = 15). a Representative plots showing the co-expression of TOX and immune checkpoint (IC) molecules (PD-1, TIM-3, and TIGIT) in the TI
CD8+ T cells. b Percentage of TOX+ cells in the two subpopulations of the TI CD8+ T cells (expressing or not expressing a specific IC molecule).
Each line in the graph indicates the data derived from the same tumor tissue of each individual patient. c TOX protein levels in the three subsets
of TI CD8+ T cells with different severities of exhaustion, i.e., PD-1−TIM-3− (orange), PD-1+TIM-3− (blue), and PD-1+TIM-3+ (red). Histogram
represents TOX expression level in each subset of the TI CD8+ T cells. Percentage of TOX-expressing cells in each subset is described in the
histogram, and mean fluorescence intensity (MFI) for TOX expression in each subset is indicated in parenthesis. A dashed line represents the
boundary separating the TOX protein expression. Distribution of TOX-expressing subsets of TI CD8+ T cells across patients is summarized in
grouped scattered plots. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001. All statistical analyses were performed using unpaired Student’s
t test
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CD8+ T cells. The TI lymphocytes derived from tumor
tissue of patients with NSCLC were transfected with
TOX siRNA. Interestingly, the knockdown of TOX in
the TI CD8+ T cells resulted in a significant reduction of
cells expressing IC molecules, such as PD-1, TIM-3,
TIGIT, and CTLA-4. On the other hand, TOX knock-
down did not lead to the statistically consistent pattern
of change in the percentage of LAG-3- or 2B4-
expressing TI CD8+ T cells (Fig. 4a). These results indi-
cate that TOX positively regulates the expression of vari-
ous IC molecules to promote CD8+ T cell exhaustion in
human cancer. Additionally, we observed that the fre-
quency of TI CD8+ T cells that secrete effector cytokines
(IFN-γ and TNF-α) significantly increased upon TOX
knockdown, suggesting that the anti-tumor function of
TI CD8+ T cells could be restored upon TOX knock-
down (Fig. 4b). Taken together, these observations sug-
gest that TOX is a key regulator of terminally exhausted
CD8+ T cell differentiation in human cancer.
TOX expression level in TI T cells is predictive for overall
survival and anti-PD-1 efficacy in human cancers
As T cells play a major role in eliminating the cancer
cells from tumors, their functional state affects the prog-
nosis and therapeutic efficacy. In this study, the single-
cell transcriptome profiles of melanoma patients
Fig. 4 TOX-dependent regulation of the expression of immune checkpoint (IC) molecules and the production of effector cytokines in the tumor-
infiltrating (TI) CD8+ T cells in human non-small cell lung cancer (NSCLC). a The expression level of IC molecules in the TI CD8+ T cells in human
NSCLC when TOX has been knocked down. b Production of IFN-γ and TNF-α in the TI CD8+ T cells in human NSCLC when TOX has been
knocked down. Each line in the graph indicates data derived from the same tumor tissue of each individual patient. ns, not significant; *P < 0.05;
**P < 0.01; ***P < 0.001. All statistical analyses were performed using paired Student’s t test
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indicated that TOX exhibited a highly specific expression
pattern in the T cells [6] (Fig. 5a). As there was a correl-
ation between TOX expression and TI CD8+ T cell ex-
haustion, we hypothesized that TOX expression in the
TI T cells may be used as a clinical indicator during can-
cer treatment. To test this hypothesis, we analyzed the
TCGA survival data with respect to the corrected TOX
expression level to evaluate the effect of T cell levels
within each sample by classifying the TOX expression
based on the geometric mean of CD3 gene expression
levels (CD3D, CD3E, and CD3G) as described in a previ-
ous study [41]. We examined the TOX expression level
not only in TI CD8+ T cells but also in CD4+ T cells.
Some portion of the normalized TOX expression in the
T cells originates from CD4+ T cells, which cannot be
negated by a marker-based normalization approach.
However, if the TOX expression level in the T cells is
positively correlated with that in the CD8+ T cells, the
TOX level in all T cells would be proportional to that of
CD8+ T cells. The analysis of single-cell transcriptome
data from patients with melanoma [6] revealed a strong
positive correlation between TOX expression level in all
T cells and in CD8+ T cells (Fig. 5b). This enabled the
evaluation of differences in the overall survival between
cancer patients exhibiting varying TOX expression levels
in the TI T cells. The low TOX expression level in the T
cells was associated with enhanced overall survival rate
(P = 0.0022, log-rank test) for TCGA melanoma cohort
(SKCM, skin cutaneous melanoma) (Fig. 5c). Similarly,
the survival analysis of TCGA NSCLC cohort (LUAD,
lung adenocarcinoma, and LUSC, lung squamous cell
carcinoma) revealed that a high overall survival rate was
associated with low TOX expression level in the T cells
(P = 0.0393, log-rank test) (Fig. 5d). A similar analysis
was applied to other cancer types in TCGA cohort,
which revealed that the survival rate of patients with
bladder cancer (BLCA, bladder urothelial carcinoma),
head and neck cancer (HNSC, head and neck squamous
cell carcinoma), sarcoma (SARC, sarcoma), and uterine
cancer (UCEC, uterine corpus endometrial carcinoma)
Fig. 5 TOX expression level in the tumor-infiltrating (TI) T cells can predict prognosis and anti-PD-1 therapy response. a Violin plots to depict the
distribution of TOX expression levels for three groups of cells derived from melanoma: T cells, other immune cells, and cancer cells. b Correlation
between TOX expression level in the T cells and TOX expression level in the CD8+ T cells. c Overall survival analysis of The Cancer Genome Atlas
(TCGA) cohorts of patients with subcutaneous melanoma (SKCM). d Overall survival analysis of TCGA cohorts of patients with non-small cell lung
cancer (NSCLC) (with only the top 25% tumor mutation burden). The patients were classified into high-TOX for those with top 30% TOX-level and
low-TOX for the rest. e–g Waterfall plot to depict anti-PD-1 immunotherapy response based on three independent cohorts of patients with
melanoma from Hugo et al. (e), patients with NSCLC from Jung et al. (f), and patients with NSCLC recruited from Yonsei Cancer Center (YCC) (g).
The baseline represents median level of TOX expression normalized to the level in the TI T cells. P values are calculated using the two-tailed
Mann-Whitney U test (testing the association of responder status with level of TOX expression in TI T cells). h Area under the receiver operating
characteristics curve (AUROC) for the retrieval of responders based on the TOX expression level in the TI T cells
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was associated with low TOX expression level in the TI
T cells (Additional file 2: Figure S5). Notably, anti-PD-1
therapy has been approved by the US FDA (Food and
Drug Administration) for treating bladder cancer and
head and neck cancer. These results suggest that TOX
expression levels in the TI T cells can be used to predict
the overall survival of patients with cancer.
Next, we evaluated the power of TOX expression level
in the TI T cells to predict the response to anti-PD-1
immunotherapy by analyzing the bulk RNA-seq data
and clinical information in previously published reports
regarding independent patient cohorts who underwent
anti-PD-1 therapy. Interestingly, the TOX expression
level in the TI T cells was inversely correlated with the
anti-PD-1 immunotherapy response in two published
cohorts of patients with cancer, i.e., melanoma cohorts
[19] (Fig. 5e) and NSCLC cohorts [21] (Fig. 5f). A similar
analysis was performed on our internal cohort of pa-
tients with NSCLC recruited from Yonsei Cancer Center
in Korea, which revealed a similar inverse correlation be-
tween TOX expression level in the TI T cells and anti-
PD-1 responses (Fig. 5g). In the two NSCLC cohorts, the
TOX expression level in the TILs of responders was sig-
nificantly lower than that in the TILs of non-responders
(P = 0.016 and 0.002, two-tailed Mann-Whitney U test).
Furthermore, we prioritized the patients exhibiting the
lowest TOX expression level in the TI T cells. This
stratification revealed high area under the receiver oper-
ating characteristic curve (AUROC) scores, which indi-
cated that low TOX expression was a predictive marker
for anti-PD-1 therapy response (Fig. 5h). The prediction
of the anti-PD-1 response based on the TOX expression
level in the TI T cells was not effective in another pub-
lished cohort of patients with melanoma [20]. The rela-
tive abundance of TI T cells in this cohort was
significantly lower than that in the three predictive co-
horts (Additional file 2: Figure S6), which explains the
poor predictive power of TOX expression in T cells for
anti-PD-1 response. Therefore, we suggest that TOX ex-
pression level in the TI T cells can be a useful predictor
for anti-PD-1 efficacy in human cancer. In summary,
these results suggest that TOX expression level in the TI
T cells can be used for patient stratification in cancer
treatment, including anti-PD-1 immunotherapy.
Discussion
In this study, we identified the regulatory factors in-
volved in TI CD8+ T cell exhaustion by analyzing the
scRNA-seq data using a method that mimics the subset
analysis of flow or mass cytometry data. In contrast to
conventional cytometry that can quantify a maximum of
50 pre-selected proteins, the scRNA-seq enables
genome-wide expression analysis at the transcript level.
The unbiased search for genes that are co-expressed
with PDCD1, which is a major marker gene for T cell
exhaustion, revealed not only IC genes but also TFs in-
volved in T cell exhaustion, such as BATF, NFATC1,
and PRDM1. The novel candidate genes reported in this
study would be useful sources for future investigations
on the molecular process underlying T cell exhaustion.
A limitation of our prediction approach is that some
genes that are not co-expressed with PDCD1, but are in-
volved in the regulation of T cell exhaustion, may be
missed. This limitation could be partially overcome by
using additional marker genes for T cell exhaustion,
such as TIM-3 and LAG-3.
Our results demonstrated the effectiveness of subset
analysis using the scRNA-seq data to identify the regula-
tory molecules mediating cellular transitions across a
continuous spectrum of transcriptional states. Recently,
we published a web server, VirtualCytometry [42], which
enables interactive subset analysis of public scRNA-seq
datasets for human and mouse immune cells derived
from various tissues, including tumors. Users can repro-
duce the gene prioritization for T cell exhaustion using
the web server. The proposed method may be applied
for studying cellular differentiation of various immune
cells with appropriate marker genes.
Applying the subset analysis described in this study to
the single-cell transcriptome profiles of CD8+ T cells
from human melanoma and NSCLC, which are currently
the two most prevalent cancer types treated by anti-PD-
1 therapy in the clinic, we could identify TOX as the top
candidate TF for both cancer types. Previously, TOX
was reported to regulate the development of CD4+ T
cells, natural killer cells, and lymphoid tissue inducer
cells [43]. A series of recent studies reported that TOX
promotes CD8+ T cell exhaustion in chronic viral infec-
tion and cancer [30–32, 44–47]. Using the scRNA-seq
data generated from human tumor samples, we also in-
dependently demonstrated that TOX promotes CD8+ T
cell exhaustion in human cancer. The analysis of expres-
sion dynamics in single-cell trajectories, and the flow cy-
tometry analysis of expression correlation demonstrated
that TOX is a more influential regulator of CD8+ T cell
exhaustion than other known factors in human cancer.
Therefore, inhibition of TOX may potentially inhibit the
cellular differentiation program in the generation of ter-
minally exhausted T cells, thereby consequently enhan-
cing the reinvigoration potential of progenitor exhausted
T cells. To the best of our knowledge, this is the first
study to demonstrate the feasibility of patient stratifica-
tion for evaluating the anti-PD-1 therapy response based
on the TOX expression level in TI T cells for multiple
types of cancer (melanoma and lung cancer). Therefore,
development of TOX-based biomarkers for prognosis of
anti-cancer treatment and anti-PD-1 response can help
in the improvement of cancer immunotherapy.
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Previous studies have demonstrated that NFAT induces
the expression of TOX, TOX2, and NR4A1 [29, 30]. The
flow cytometric analysis revealed that there was a signifi-
cant difference in the proportion of TOX+ cells among
the TI CD8+ T cells exhibiting and not exhibiting PD-1
expression, which was not observed for NR4A1+ cells (see
Additional file 2: Figure S1C). Consistently, there was no
significant difference in NR4A1 levels between the effector
cells and exhausted cells in the single-cell trajectory. How-
ever, the expression of NR4A1 was upregulated at later
stages of the exhaustion process (see Fig. 2d). The cross-
regulation between TOX and NR4A1 is unknown. TOX
knockdown in the TI CD8+ T cells significantly downreg-
ulated the expression of IC molecules, such as PD-1
(Fig. 4a), but not those of NR4A1 (Additional file 2:
Figure S7). This indicated that TOX does not regulate
NR4A1. Additionally, TOX and NR4A1 may inde-
pendently contribute to T cell exhaustion. However,
the possibility of NR4A1 regulating TOX as an up-
stream regulator cannot be ruled out. It would be in-
teresting to investigate if TOX and NR4A1 can
regulate each other at the transcriptional level, and to
determine the more effective factor among the two
with respect to T cell exhaustion.
One of the most common applications of single-cell
transcriptome data is pseudotime analysis, which recon-
structs the biological processes by exploiting the hetero-
geneity of cell population. Using highly heterogeneous
CD8+ T cells in the tumor, we could successfully recon-
struct the trajectories from effector state into either
memory or exhausted state by pseudo-temporal ordering
of cells in the low-dimensional latent space based on the
transcriptome profiles of individual cells. Next, we di-
vided the cells into effector, memory, and exhausted
cells based on the branching point of the trajectories to
confirm the expression dynamics of many known regula-
tors of T cell exhaustion. The trajectories of the cells
also enabled us to perform differential expression ana-
lysis between short pseudo-temporal stages, such as be-
tween late effector state and early exhausted state to
identify regulators that upregulate or maintain TOX. A
detailed analysis of the single-cell transcriptome data will
facilitate the unraveling of the regulatory circuit involved
in CD8+ T cell exhaustion.
Conclusions
To identify regulatory factors promoting T cell exhaus-
tion in the tumor microenvironment, we prioritized TFs
by differential expression between two subsets of TI
CD8+ T cells divided by different levels of PDCD1 ex-
pression. We found that TOX levels positively correlate
with those of IC molecules in human melanoma and
NSCLC. The expression dynamics along the pseudo-
temporally ordered CD8+ T cells from human tumors
revealed that the expression of TOX increases with the
exhaustion of CD8+ T cells. In addition, TOX knock-
down in TI CD8+ T cells from human tumor reduced
the number of cells expressing PD-1, TIM-3, TIGIT,
and CTLA-4. These results indicate that TOX promotes
T cell exhaustion via positive regulation of IC molecules.
We also observe that TOX level in the TI T cells in-
versely correlates with overall survival and anti-PD-1 re-
sponse in human melanoma and NSCLC, which suggest
that TOX expression in the TI T cells can be used for
patient stratification before anti-tumor immunotherapy,
such as anti-PD-1 treatment. Taken all these results to-
gether, we propose TOX as a positive regulator for T
cell exhaustion and a predictor for anti-PD-1 responses
in human cancer. TOX inhibition may potentially im-
pede T cell exhaustion and improve ICI efficacy.
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